San Antonio, May 16, 2017 -- For immediate release
|
|||
Southwest Research Institute® (SwRI®) has tapped has tapped into mobile communications technology to turbocharge its custom Rhodium Drug Development System. Rhodium, SwRI’s proprietary docking simulation program for biostructure-based drug design, has improved its processing capabilities up to four times faster thanks to a new SwRI-designed and optimized “super computer” that uses the same technology found in mobile communications to enable faster streaming.
“Even before the integration of cell phone technology, the Rhodium software program represented a significant improvement in drug discovery by automatically searching the complete 3-D structure of a protein,” said Dr. Jonathan Bohmann, a principal scientist in SwRI’s Chemistry and Chemical Engineering Division. “Our clients are very excited about the advantages the increased processing power offers.”
When designing a new drug, researchers must understand how a drug or series of similar compounds (known as ligands) will bind with, or inhibit, proteins. SwRI’s Rhodium software prescreens the three-dimensional structure of proteins and enzymes, accelerating pharmaceutical and biochemical research prior to drug development. Even with Rhodium’s rapid turnaround time, clients needed even faster processing capabilities.
Mobile technology is designed to be power efficient. Integrating this technology, SwRI designed and optimized a super computer about the size of a filing cabinet. The unit is secured, ensuring client information remains protected.
“A lot of processing power fits in this compact package,” Bohmann said. “With no external connection the processing happens right here at SwRI, keeping our clients’ information secure. Rhodium is powerful, streaming fast, secure, and efficient.”
After undergoing pilot acceptance tests in early 2017, the processing system is now fully activated.
“The processing results are four times faster than the previous generation,” Bohmann said. “The supercomputer unit is modular and more components can be added as needed to increase processing capacity.”
Rhodium can be used to develop and screen a range of drugs from antibiotics to treatments for diseases from cancer to Alzheimer’s as well as vaccines. The software also predicts adverse drug reactions and side effects. Recently Rhodium was a topmost performer in a community-wide blind docking challenge for predicting drug potency hosted by the Drug Design Data Resource.
To learn more about SwRI, see microencapsulation.swri.org or visit Booth No. 1341 at INFORMEX.
------------------------------------------------
About SwRI:
SwRI is an independent, nonprofit, applied research and development organization based in San Antonio, Texas, with nearly 2,700 employees and an annual research volume of $559 million. In 2017, SwRI celebrates 70 years of benefiting government, industry and the public with innovative R&D. Visit newsroom.swri.org for more SwRI developments.
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/fd074930-755f-4ed8-8bf6-22337493edd4
Attachments:
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/82c6a5e3-b63a-4c47-86b2-42823c280979
Tracey M.S. Whelan Southwest Research Institute 210-522-2256 [email protected]


Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 



